Develops drugs for autoimmune diseases.
Dec 2024Revenue $451K/yrExpenses $2.62M/yr
No trendCash runway ≈ 3 months from Dec 2024
Figures by year
When will XTL Biopharmaceuticals be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2024, revenue was $451K and expenses $2.62M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2024 | $451K | $2.62M | −$2.17M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.